The significance of serum hepatocyte growth factor levels in planning follow-up of postoperative jaundice-free patients with biliary atresia

J Pediatr Surg. 2006 Oct;41(10):1657-62. doi: 10.1016/j.jpedsurg.2006.05.058.

Abstract

Purpose: The aim of this study was to clarify the significance of serum hepatocyte growth factor (HGF), interleukin (IL)-6, and IL-1 receptor antagonist (ra) levels in the evaluation of disease status in jaundice-free survivors with biliary atresia after Kasai operation.

Patients and methods: Serum concentrations of HGF, IL-6, and IL-ra were measured in 31 long-term jaundice-free patients with biliary atresia after Kasai operation and 29 controls. Patients were divided into 4 groups: group A (n = 8), normal liver function; group B (n = 9), mild liver dysfunction without portal hypertension; group C (n = 9), moderate liver dysfunction with controllable portal hypertension; and group D (n = 5), receiving liver transplantation.

Results: Serum IL-6 levels were significantly higher in patients than in controls. There was no difference in serum IL-6 levels among groups B, C, and D. Serum IL-1ra levels were elevated according to liver dysfunction. Serum HGF levels in group D were significantly higher than in controls and the other groups. Serum hyaluronic acid levels were positively correlated with serum levels of IL-1ra and HGF.

Conclusions: Elevation of serum IL-1ra and HGF levels correlated with the progression of liver fibrosis and dysfunction. In particular, serum HGF levels could be used as a predictor for requiring liver transplantation.

MeSH terms

  • Biliary Atresia / blood*
  • Biliary Atresia / complications
  • Biliary Atresia / surgery*
  • Child, Preschool
  • Disease Progression
  • Hepatocyte Growth Factor / blood*
  • Humans
  • Infant
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-6 / blood*
  • Jaundice / etiology
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / diagnosis
  • Liver Diseases / blood
  • Liver Diseases / diagnosis
  • Liver Diseases / physiopathology
  • Patient Care Planning*
  • Portoenterostomy, Hepatic*
  • Postoperative Care*
  • Postoperative Complications / blood
  • Postoperative Complications / diagnosis
  • Postoperative Complications / therapy
  • Sialoglycoproteins / blood*
  • Treatment Outcome

Substances

  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-6
  • Sialoglycoproteins
  • Hepatocyte Growth Factor